An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features

H.-J. Seo; B. C. Lee; J.-H. Seok; H. J. Jeon; J.-W. Paik; W. Kim; K.-P. Kwak; C. Han; K.-U. Lee; C.-U. Pae

doi:10.1055/s-0033-1353171

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2013; 46(06): 221-226
DOI: 10.1055/s-0033-1353171

Original Paper

An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features

Authors

H.-J. Seo

¹Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
B. C. Lee

²Department of Neuropsychiatry, College of Medicine, Hallym University, Seoul, Korea
J.-H. Seok

³Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea
H. J. Jeon

⁴Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
J.-W. Paik

⁵Department of Psychiatry, Kyunghee University College of Medicine, Seoul, Korea
W. Kim

⁶Department of Psychiatry, College of Medicine, Inje University, Seoul, Korea
K.-P. Kwak

⁷Department of Neuropsychiatry, School of Medicine, Dongguk University, Gyeongju, Korea
C. Han

⁸Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea
K.-U. Lee

¹Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea
C.-U. Pae

¹Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea

⁹Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Duram, NC, USA

Abstract

Objectives:

The present study aimed at investigating the effectiveness and tolerability of bupropion hydrochloride extended release (XL) in major depressive disorder (MDD) patients with atypical features (AF).

Methods:

51 patients were prescribed bupropion XL for 8 weeks (6 visits: screening, baseline, weeks 1, 2, 4 and 8). The primary efficacy measure was a change of the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD) from baseline to endpoint. Secondary efficacy measures included the SIGH-SAD atypical symptoms subscale, Clinical Global Impression–Severity (CGI-S), Sheehan Disability Scale (SDS) and Epworth Sleepiness Questionnaire (ESQ). Response or remission was defined as ≥50% reduction or ≤7 in SIGH-SAD total scores, respectively, at end of treatment.

Results:

The HAM-D-29 total score reduced by 55.3% from baseline (27.3±6.5) to end of treatment (12.2±6.3) (p<0.001). Atypical symptom subscale scores also reduced by 54.5% from baseline (9.2±3.0) to end of treatment (4.2±2.8) (p<0.001). At the end of treatment, 24.4% (n=10) and 51.2% (n=21) subjects were classified as remitters and responders, respectively. The most frequently reported AEs were headache (13.7%), dry mouth (11.8%), dizziness (9.8%), and dyspepsia (9.8%).

Conclusions:

Our preliminary study indicates that bupropion XL may be beneficial in the treatment of MDD with atypical features. Adequately powered, randomized, double-blind, placebo-controlled trials are necessary to determine our results.

Key words

bupropion XL - atypical depression - effectiveness - remission - response - tolerability

Full Text

References

References
1 American Psychiatric Association . Diagnostic and Statistical Manual. Fourth Edition. DSM-IV; 1994
2 Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry 2007; 68 (Suppl 8): 11-16
3 Angst J, Gamma A, Sellaro R et al. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002; 72: 125-138
4 Stewart JW, McGrath PJ, Rabkin JG et al. Atypical depression. A valid clinical entity?. Psychiatr Clin North Am 1993; 16: 479-495
5 Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996; 37: 375-383
6 Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. American J Psychiatry 1995; 152: 31-36
7 Quitkin FM, Rabkin JG, Stewart JW et al. Sleep of atypical depressives. J Affect Disord 1985; 8: 61-67
8 Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. J Clin Psychiatry 2007; 68: e10
9 Quitkin FM, Stewart JW, McGrath PJ et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145: 306-311
10 Quitkin FM, McGrath PJ, Stewart JW et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry 1990; 47: 935-941
11 Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129-137
12 Liebowitz MR, Quitkin FM, Stewart JW et al. Phenelzine v imipramine in atypical depression. A preliminary report. Arch Gen Psychiatry 1984; 41: 669-677
13 Stratta P, Bolino F, Cupillari M et al. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991; 6: 193-196
14 McGrath PJ, Stewart JW, Janal MN et al. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 2000; 157: 344-350
15 Sogaard J, Lane R, Latimer P et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. J Psychopharmacol 1999; 13: 406-414
16 Pande AC, Birkett M, Fechner-Bates S et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996; 40: 1017-1020
17 Lonnqvist J, Sihvo S, Syvalahti E et al. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 1994; 32: 169-177
18 Henkel V, Mergl R, Allgaier AK et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006; 141: 89-101
19 Pae CU, Masand PS, Peindl K et al. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. Prim Care Companion. J Clin Psychiatry 2008; 10: 205-210
20 Falkai P. Mirtazapine: other indications. J Clin Psychiatry 1999; 60 (Suppl. 17) 36-40 discussion 46-38
21 Roose SP, Miyazaki M, Devanand D et al. An open trial of venlafaxine for the treatment of late-life atypical depression. Int J Geriatr Psychiatry 2004; 19: 989-994
22 Stewart JW, Deliyannides DA, McGrath PJ. Is duloxetine effective treatment for depression with atypical features?. Int Clin Psychopharmacol 2008; 23: 333-336
23 Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7: 92-95
24 Stahl SM, Pradko JF, Haight BR et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6: 159-166
25 Marks DM, Thanaseelan J, Pae CU. Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig 2009; 6: 1-6
26 Pae CU, Tharwani H, Marks DM et al. Atypical depression: a comprehensive review. CNS Drugs 2009; 23: 1023-1037
27 Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008; 5: 142-147
28 Fava M, Rush AJ, Thase ME et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion. J Clin Psychiatry 2005; 7: 106-113
29 Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67: 736-746
30 McGinn LK, Asnis GM, Rubinson E. Biological and clinical validation of atypical depression. Psychiatry Res 1996; 60: 191-198
31 Montgomery SA. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008; 23: 63-69
32 Jimerson DC, Lesem MD, Kaye WH et al. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 1992; 49: 132-138
33 Aklillu E, Karlsson S, Zachrisson OO et al. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression. Pharmacogenet Genomics 2009; 19: 267-275
34 Papakostas GI, Nutt DJ, Hallett LA et al. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60: 1350-1355
35 Pae CU, Lim HK, Han C et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother 2007; 7: 1251-1263
36 Jefferson JW, Rush AJ, Nelson JC et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 865-873
37 MINI . Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20) 22-33 quiz 34–57
38 SIGH-SAD . Williams M, Link N, Rosenthal L et al. Structured interview guide for the Hamilton Depression Rating Scale – Seasonal affective disorder version. Society for Light Treatment and Biological Rhythms; Wilsonville, OR: 1988
39 CGI-S . Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976
40 SDS . Sheehan D. The anxiety disease. New York, NY: Scribner and Sons; 1983
41 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545
42 Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22: 343-381
43 Thase ME, Clayton AH, Haight BR et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26: 482-488
44 GlaxoSmithKline. Wellbutrin (bupropion hydrochloride): US prescribing information [online]. Available from URL http://www.fda.gov/cder/foi/label/2007/018644s036lbl.pdf
45 GlaxoSmithKline. Wellbutrin SR (bupropion hydrochloride sustained-release tablets): US prescribing information [on line]. Available from URL: http://www.fda.gov/cder/foi/label/2007/020358s043lbl.pdf [Accessed 2013 Jan 15]
46 Croft HA, Wightman D, Hewett K et al. Additional data on the safety and tolerability of bupropion extended-release: newly accumulated data extends previous findings in placebo controlled clinical trials [abstract no. NR484 plus poster]. 159^th Annual Meeting of the American Psychiatric Association 2006 Toronto (ON)